Iris Wai Sum Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Iris Wai Sum Li has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alvin Chi Keung Lai
Department of Architecture and Civil Engineering, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong
2 shared publications A.C.-K. Lai
1 shared publicationB.R. Chen
1 shared publicationC.-M. Lo
1 shared publication- Chris Ka Pun Mok
The Chinese University of Hong Kong
1 shared publication - Dongrong Lu
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in Results in Engineering
- Vol. 32
Far-UVC and UVC disinfection of healthcare fabrics: from laboratory evidence to clinical application
- 23 September 2026
- Published by Elsevier in Results in Engineering
- Vol. 32
Open AccessFar-UVC and UVC disinfection of healthcare fabrics: from laboratory evidence to clinical application
- 17 November 2024
- Published by Elsevier in Building and Environment
- Vol. 267
Experimental investigation comparing Far-UVC (222nm) and UVC (254nm) for inactivation of bacteria on hard and fabric surfaces
- 17 November 2024
- Published by Elsevier in Building and Environment
- Vol. 267
Experimental investigation comparing Far-UVC (222nm) and UVC (254nm) for inactivation of bacteria on hard and fabric surfaces
- Open Access
- 3 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (22) , eabn6064
Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees
Various COVID-19 vaccines are currently deployed, but their immunization varies and decays with time. Antibody level is a potent correlate to immune protection, but its quantitation relies on intensive laboratory techniques. Here, we report a decentralized, instrument-free microfluidic device that directly visualizes SARS-CoV-2 antibody levels. Magnetic microparticles (MMPs) and polystyrene microparticles (PMPs) can bind to SARS-CoV-2 antibodies simultaneously. In a microfluidic chip, this binding reduces the incidence of free PMPs escaping from magnetic separation and shortens PMP accumulation length at a particle dam. This visual quantitative result enables use in either sensitive mode [limit of detection (LOD): 13.3 ng/ml; sample-to-answer time: 70 min] or rapid mode (LOD: 57.8 ng/ml; sample-to-answer time: 20 min) and closely agrees with the gold standard enzyme-linked immunosorbent assay. Trials on 91 vaccinees revealed higher antibody levels in mRNA vaccinees than in inactivated vaccinees and their decay in 45 days, demonstrating the need for point-of-care devices to monitor immune protection.
- 3 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (22) , eabn6064
Open AccessMicrofluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees
Various COVID-19 vaccines are currently deployed, but their immunization varies and decays with time. Antibody level is a potent correlate to immune protection, but its quantitation relies on intensive laboratory techniques. Here, we report a decentralized, instrument-free microfluidic device that directly visualizes SARS-CoV-2 antibody levels. Magnetic microparticles (MMPs) and polystyrene microparticles (PMPs) can bind to SARS-CoV-2 antibodies simultaneously. In a microfluidic chip, this binding reduces the incidence of free PMPs escaping from magnetic separation and shortens PMP accumulation length at a particle dam. This visual quantitative result enables use in either sensitive mode [limit of detection (LOD): 13.3 ng/ml; sample-to-answer time: 70 min] or rapid mode (LOD: 57.8 ng/ml; sample-to-answer time: 20 min) and closely agrees with the gold standard enzyme-linked immunosorbent assay. Trials on 91 vaccinees revealed higher antibody levels in mRNA vaccinees than in inactivated vaccinees and their decay in 45 days, demonstrating the need for point-of-care devices to monitor immune protection.
- 1 November 2020
- Published by Elsevier in Public Health
- Vol. 188, 42-50
Home-made masks with filtration efficiency for nano-aerosols for community mitigation of COVID-19 pandemic
- 1 November 2020
- Published by Elsevier in Public Health
- Vol. 188, 42-50
Home-made masks with filtration efficiency for nano-aerosols for community mitigation of COVID-19 pandemic
- Open Access
- 5 September 2017
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 11 (08) , 656-661
Sequential Mycoplasma pneumoniae pneumonia and Chromobacterium violaceum skin abscess in a pediatric patient
Mycoplasma pneumoniae is a common atypical respiratory pathogen causing community-acquired pneumonia in children. Co-infection with other respiratory viruses is common in pediatric patients but super-infection with bacteria other than Streptococcus pneumoniae and Haemophilus influenzae is rare. The first case of Chromobacterium violaceum infection incubated during and manifested after pneumonia caused by Mycoplasma pneumoniae in a 12-month old girl without any known history of immunodeficiency is here reported. The patient developed fever with redness and swelling over the middle phalanx of the right hand index finger which progressed to the formation of skin abscess. Following a course of intravenous meropenem and surgical drainage of the skin abscess, the patient fully recovered and was discharged.
- 5 September 2017
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 11 (08) , 656-661
Open AccessSequential Mycoplasma pneumoniae pneumonia and Chromobacterium violaceum skin abscess in a pediatric patient
Mycoplasma pneumoniae is a common atypical respiratory pathogen causing community-acquired pneumonia in children. Co-infection with other respiratory viruses is common in pediatric patients but super-infection with bacteria other than Streptococcus pneumoniae and Haemophilus influenzae is rare. The first case of Chromobacterium violaceum infection incubated during and manifested after pneumonia caused by Mycoplasma pneumoniae in a 12-month old girl without any known history of immunodeficiency is here reported. The patient developed fever with redness and swelling over the middle phalanx of the right hand index finger which progressed to the formation of skin abscess. Following a course of intravenous meropenem and surgical drainage of the skin abscess, the patient fully recovered and was discharged.
- 15 May 2017
- Published by Wiley in Transplant Infectious Disease
- Vol. 19 (3)
Acute hepatitis E virus infection causing acute liver failure requiring living‐donor liver transplantation in a non‐pregnant immunocompetent woman
We report a rare case of acute liver failure from acute hepatitis E virus (HEV) in a non‐pregnant woman without comorbidities who survived after liver transplantation. The source was likely consumption of partially cooked pig liver. HEV genotype 3 is the second most common genotype causing acute hepatitis E in developed countries. Fulminant hepatitis E rarely occurs without a risk factor, as in our patient. Vigilant monitoring for chronic hepatitis E in post‐transplant immunocompromised patients is needed.
- 15 May 2017
- Published by Wiley in Transplant Infectious Disease
- Vol. 19 (3)
Acute hepatitis E virus infection causing acute liver failure requiring living‐donor liver transplantation in a non‐pregnant immunocompetent woman
We report a rare case of acute liver failure from acute hepatitis E virus (HEV) in a non‐pregnant woman without comorbidities who survived after liver transplantation. The source was likely consumption of partially cooked pig liver. HEV genotype 3 is the second most common genotype causing acute hepatitis E in developed countries. Fulminant hepatitis E rarely occurs without a risk factor, as in our patient. Vigilant monitoring for chronic hepatitis E in post‐transplant immunocompromised patients is needed.